Cancer Chemotherapy and Pharmacology

, Volume 81, Issue 6, pp 999–1006 | Cite as

Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner

  • Fei Wu
  • Yun Lin
  • Peng Cui
  • Hongyun Li
  • Lechao Zhang
  • Zeqiang Sun
  • Shengliang Huang
  • Shun Li
  • Shiming Huang
  • Qingli Zhao
  • Qingyong Liu
Original Article



At least to date, no effective treatment for advanced castration-resistant prostate cancer (CRPC) has been established. Recent studies indicated that cell division cycle 20 homolog (Cdc20) overexpression is associated with poor prognosis in patients with castration-resistant prostate cancer. However, the mechanism of Cdc20 in the development of docetaxel resistance in CRPC remains elusive.


In this study, the transcription of Cdc20 was confirmed in three independent CRPC cell lines derived from different tissues, including LNCaP, PC3, and DU145. Docetaxel resistant (DR) cell lines were generated within the background of DU145 and PC3. The protein levels of Cdc20 and the biological phenotype were detected in both wild-type and DR cell lines. To further explore the mechanism of Cdc20 overexpression, stable cell lines with Cdc20 or Bcl-2 interacting mediator of cell death (Bim) deprivation were generated and examined for biological parameters. In addition, a specific Cdc20 inhibitor was used in DR cell lines to explore the potential solution for docetaxel resistant CRPC.


Here, we identified Cdc20 is overexpressed in docetaxel resistant CRPC cell lines, including LNCaP, PC3, and DU145. We also reported that DR cell lines, which mimic the recurrent prostate cancer cells after docetaxel treatment, have higher levels of Cdc20 protein compared with the CRPC cell lines. Interestingly, the protein levels of Bim, an E3 ligase substrate of Cdc20, were decreased in DR cell lines compared with the wild-type, while the mRNA levels were similar. More importantly, in DR cell lines, the biological phenotype induced by Cdc20 deletion could be significantly reversed by the additional knockdown of Bim. As a result, docetaxel resistant prostate cancer cells treated with the pharmacological Cdc20 inhibitor became sensitive to docetaxel treatment.


In conclusion, our data collectively demonstrated that Cdc20 overexpression facilitates the docetaxel resistant of the CRPC cell lines in a Bim-dependent manner. Furthermore, additionally targeting Cdc20 might be a promising solution for the treatment of the CRPC with docetaxel resistance.


Cdc20 Bim Docetaxel Prostate cancer 



We thanked Dr. Yang Sun for proof reading of our manuscript, and sincerely thanked the generous help from all the members of the Department of Urology, Shandong Provincial Qianfoshan Hospital, Shandong University.


This work was supported by the National Natural Science Foundation of China (8180060968).

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest in this study.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-386CrossRefGoogle Scholar
  2. 2.
    Mitchell T, Neal DE (2015) The genomic evolution of human prostate cancer. Br J Cancer 113:193–198CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouviere O, Wiegel T, Mottet N (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71:630–642CrossRefPubMedGoogle Scholar
  4. 4.
    Lowrance WT, Roth BJ, Kirkby E, Murad MH, Cookson MS (2016) Castration-resistant prostate cancer: AUA guideline amendment 2015. J Urol 195:1444–1452CrossRefPubMedGoogle Scholar
  5. 5.
    Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, Boorjian SA, Kulkarni GS, Karnes RJ, Satkunasivam R (2017) Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: a systematic review and network meta-analysis. Eur Urol. CrossRefPubMedGoogle Scholar
  6. 6.
    Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Nakamura Y, Matsuda K (2008) CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27:1562–1571CrossRefPubMedGoogle Scholar
  7. 7.
    Wang L, Zhang J, Wan L, Zhou X, Wang Z, Wei W (2015) Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol Ther 151:141–151CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Gayyed MF, El-Maqsoud NM, Tawfiek ER, El Gelany SA, Rahman MF (2016) A comprehensive analysis of CDC20 overexpression in common malignant tumors from multiple organs: its correlation with tumor grade and stage. Tumour Biol 37:749–762CrossRefPubMedGoogle Scholar
  9. 9.
    Mao Y, Li K, Lu L, Si-Tu J, Lu M, Gao X (2016) Overexpression of Cdc20 in clinically localized prostate cancer: relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy. Cancer Biomark 16:351–358CrossRefPubMedGoogle Scholar
  10. 10.
    Wu F, Dai X, Gan W, Wan L, Li M, Mitsiades N, Wei W, Ding Q, Zhang J (2017) Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. Cancer Lett 385:207–214CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Replogle-Schwab TS, Schwab ED, Pienta KJ (1997) Development of doxorubicin resistant rat prostate cancer cell lines. Anticancer Res 17:4535–4538PubMedGoogle Scholar
  12. 12.
    Wan L, Tan M, Yang J, Inuzuka H, Dai X, Wu T, Liu J, Shaik S, Chen G, Deng J, Malumbres M, Letai A, Kirschner MW, Sun Y, Wei W (2014) APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. Dev Cell 29:377–391CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Shukla S, Saxena S, Singh BK, Kakkar P (2017) BH3-only protein BIM: an emerging target in chemotherapy. Eur J Cell Biol 96:728–738CrossRefPubMedGoogle Scholar
  14. 14.
    Peters JM (2006) The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat Rev Mol Cell Biol 7:644–656CrossRefPubMedGoogle Scholar
  15. 15.
    Hayes MJ, Kimata Y, Wattam SL, Lindon C, Mao G, Yamano H, Fry AM (2006) Early mitotic degradation of Nek2A depends on Cdc20-independent interaction with the APC/C. Nat Cell Biol 8:607–614CrossRefPubMedGoogle Scholar
  16. 16.
    Yu H (2007) Cdc20: a WD40 activator for a cell cycle degradation machine. Mol Cell 27:3–16CrossRefPubMedGoogle Scholar
  17. 17.
    Li K, Mao Y, Lu L, Hu C, Wang D, Si-Tu J, Lu M, Peng S, Qiu J, Gao X (2016) Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel. Int J Oncol 49:1679–1685CrossRefPubMedGoogle Scholar
  18. 18.
    Um HD (2016) Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species. Oncotarget 7:5193–5203CrossRefPubMedGoogle Scholar
  19. 19.
    De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, Atadja P, Jernberg-Wiklund H, Vanderkerken K (2010) IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood 115:2430–2440CrossRefPubMedGoogle Scholar
  20. 20.
    Ridinger-Saison M, Evanno E, Gallais I, Rimmele P, Selimoglu-Buet D, Sapharikas E, Moreau-Gachelin F, Guillouf C (2013) Epigenetic silencing of Bim transcription by Spi-1/PU.1 promotes apoptosis resistance in leukaemia. Cell Death Differ 20:1268–1278CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Fei Wu
    • 1
  • Yun Lin
    • 1
  • Peng Cui
    • 2
  • Hongyun Li
    • 1
  • Lechao Zhang
    • 1
  • Zeqiang Sun
    • 1
  • Shengliang Huang
    • 1
  • Shun Li
    • 1
  • Shiming Huang
    • 1
  • Qingli Zhao
    • 1
  • Qingyong Liu
    • 1
  1. 1.Department of Urology, Shandong Provincial Qianfoshan HospitalShandong UniversityJinanPeople’s Republic of China
  2. 2.Department of Out-PatientNo. 88 Hospital of PLATai’anPeople’s Republic of China

Personalised recommendations